The Cross-Border Biotech Blog

Monday Deal Review – July 28, 2014

Welcome to your Monday Biotech Deal Review for July 28th, 2014!   The past weeks saw significant activity in the financing space, with Tribute closing their public offering, worth approximately $30 million in the aggregate. Spectral and Zenith on the other hand have closed private offerings of their own, obtaining proceeds of $13.2 million and […]

read more


Q2 2014 Share Price Performance (Part 2)

    Momentum more selective in Q2 but still overall positive share price performance in H1 2014 for the Canadian Healthcare Sector (Part 2) In this blog, I am going to comment on the Q2 performance of the group of 60 companies with share prices of between $0.10 and $0.99 to start 2014. Q2 Results […]

read more


Monday Deal Review – July 14, 2014

Welcome to your Monday Biotech Deal Review for July 14th, 2014!   After a shortened week in both the US and Canada, things have picked up nicely in both the M&A and financing spaces, with Resverlogix, Spectral Diagnostics, Immunotec, Merus Labs, Helix BioPharma, Valeant and Knight each making news.   For details on these companies as […]

read more


Q2 2014 Share Price Performance (Part 1)

  Share price performance in Q2 and H1 2014 for the Canadian Healthcare Sector (Part 1): General loss of momentum but our Therapeutics – Commercial subsector of companies still surging In Q1, we asked whether there had been a fundamental strengthening of the sector’s performance and outlook or was there substantial, and perhaps unsustainable, momentum […]

read more


Monday Deal Review – June 30, 2014

Welcome to your Monday Biotech Deal Review for June 30th, 2014!   This week saw the Allergan-Valeant saga continue, with Allergan’s board telling shareholders that the current Valeant offer is “grossly inadequate, substantially undervalues the company, creates significant risks and uncertainties…and is not in the best interests of [Allergan] and its stockholders. Valeant, meanwhile, has […]

read more


Monday Deal Review – June 23, 2014

Welcome to your Monday Biotech Deal Review for June 23rd, 2014!   Valeant has continued its march towards taking control of Allergan, offering Allergan stockholders $72.00 in cash and 0.83 Valeant common shares for each share of Allergan. In addition, Merus Labs has completed a financing for gross proceeds of about $31.2 million, having issued […]

read more


Monday Deal Review – June 16, 2014

Welcome to your Monday Biotech Deal Review for June 16th, 2014!   The last two weeks saw significant activity in both the acquisition and financing spaces, so keep reading to see details on the weeks’ major biotech news. Nordion Inc. (TSX: NDN) (NYSE: NDZ) announced that its shareholders (the “Shareholders”) have approved the special resolution […]

read more


Streetwise Reports interview on the promise of Canadian Biotech

Streetwise Reports interview on the promise of Canadian Biotech As a long-time advocate for the Canadian healthcare industry, I recently had the opportunity to talk about the exciting potential of Canadian biotech companies in an interview with the life science writer from Streetwise Reports. You can see the full article here. As with all our […]

read more


Monday Deal Review – June 2, 2014

Welcome to your Monday Biotech Deal Review for June 2nd, 2014!   Valeant has sweetened the offer for Allergan shareholders this past week, raising the bid to $72.00 in cash and 0.83 in Valeant common stock. We will continue to cover the story as it develops. Hit the break for the full rundown of this […]

read more